US · Healthcare · Biotechnology
EPS came in at -1.18 against a street estimate of -1.41 — a beat of 16.3%.
Analysts rate Tectonic Therapeutic, Inc. a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $76.62.
| Fund | Stake |
|---|---|
| FMR Inc | 14.48% |
| TCG Crossover Management, LLC | 6.16% |
| Aberdeen Group PLC | 5.84% |
| BlackRock Inc | 4.41% |
| First Light Asset Management, LLC | 4.10% |
| Baker Bros Advisors LP | 3.11% |
| 5AM Venture Management, LLC | 3.10% |
| BRAIDWELL LP | 3.05% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tectonic Therapeutic, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.